Last update: Aug. 30, 2018
Minimal risk for breastfeeding and infant.
A human monoclonal antibody which inhibits the interleukin 6 (IL-6) receptor used in the treatment of rheumatoid arthritis, some forms of juvenile arthritis and in Castleman's disease.
Intravenous administration every 4 weeks.
Its use is authorized in Pediatrics from 2 years of age.
Its very high molecular weight explains the minute transfer to breastmilk which has been observed (Saito 2018). The maximum concentration in milk occurs on the third day and is so low (68 to 148 nanograms/L), that the relative dose that day would be a maximum of 0.007% (Saito 2018).
Its low oral bioavailability suggests that transfer to the infant's plasma from ingested breastmilk is nil or insignificant, except in premature infants and the immediate neonatal period, when there may be greater intestinal absorption.
No clinical, developmental or immunization (vaccines) problems have been observed in infants whose mothers were taking it (Nakajima 2016), during the first 9 to 12 months of life (Saito 2018, Salonga 2018).
Several medical associations, experts and expert consensus consider the use of this medication to be compatible or probably compatible during breastfeeding (Briggs 2017, Götestam 2016) if there are no other safer options available.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM